

## DESCRIPTION

|                           |   |
|---------------------------|---|
| <b>Species Reactivity</b> | Human   |
| <b>Specificity</b>        | Detects human Paxillin in Western blots.  |
| <b>Source</b>             | Monoclonal Mouse IgG <sub>2B</sub> Clone # 492918   |
| <b>Purification</b>       | Protein A or G purified from hybridoma culture supernatant  |
| <b>Immunogen</b>          | <i>E. coli</i> -derived recombinant human Paxillin<br>Asn59-Ser274<br>Accession # P49023                    |
| <b>Formulation</b>        | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. |


## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the [Technical Information](#) section on our website.

|                            | Recommended Concentration | Sample    |
|----------------------------|---------------------------|-----------|
| <b>Western Blot</b>        | 1 µg/mL                   | See Below |
| <b>Immunocytochemistry</b> | 8-25 µg/mL                | See Below |


## DATA

### Western Blot




**Detection of Human Paxillin by Western Blot.** Western blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human Paxillin Monoclonal Antibody (Catalog # MAB4259) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific diffuse band was detected for Paxillin at approximately 65 to 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

### Immunocytochemistry



**Paxillin in Detroit 551 Human Cell Line.** Paxillin was detected in immersion fixed Detroit 551 human embryonic skin fibroblast cell line using Mouse Anti-Human Paxillin Monoclonal Antibody (Catalog # MAB4259) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (yellow; Catalog # NL007) and counterstained with DAPI (blue). View our protocol for [Fluorescent ICC Staining of Cells on Coverslips](#).

### Immunocytochemistry



**Paxillin in HUVEC Human Cells.** Paxillin was detected in immersion fixed HUVEC human umbilical vein endothelial cells using Mouse Anti-Human Paxillin Monoclonal Antibody (Catalog # MAB4259) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to actin filament tips. View our protocol for [Fluorescent ICC Staining of Cells on Coverslips](#).

## PREPARATION AND STORAGE

|                                |   |
|--------------------------------|---|
| <b>Reconstitution</b>          | Reconstitute at 0.5 mg/mL in sterile PBS.   |
| <b>Shipping</b>                | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.   |
| <b>Stability &amp; Storage</b> | <p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul> |

## BACKGROUND

The cytoskeletal adaptor protein Paxillin is found at the interface between actin filaments and the plasma membrane. Paxillin localizes to focal adhesions, where it provides a platform for the integration and coordination of adhesion- and growth factor-related signals. Paxillin phosphorylation is required for integrin-mediated cytoskeletal reorganization, and may play a role in the disassembly of focal adhesions and stress fibers during cellular transformation. Increased Paxillin protein levels have also been reported in several malignancies, including renal, lung, and breast carcinomas.